BIT's 16th Annual Congress of International Drug Discovery Science & Technology-China 2018

The 16th Annual Congress of International Drug Discovery Science & Technology-China 2018  ( IDDST-China 2018) will be held on November 6-8, 2018 in the beautiful city of Jinan, China.

Given the major worldwide importance in drug research, new drug trials, and disease therapies, we should not only help ensure we’re apprised of current developments in the field but also reflect on new progress and look toward future challenges. IDDST-China 2018 enables presenters and delegates to enjoy the state of the art oral and poster presentations covering the recent advances from new drug discovery to clinical treatment .

IDDST-2018 will provide a unique and ideal opportunity in life sciences of Drug Discovery, practical pharmaceutical sciences, clinical studies, industrial R & D and pipeline new drugs and translational medicine for industrial executives, academic professors, investors, marketing people and governmental policymakers. With the participation of outstanding international experts, we hope productive discussions would stimulate new creative ideas of latest developments in drug discovery and therapy.

We hope your participation would contribute to your professional development and relationships. Wish you enjoy the conference.

Preliminary Program
Stream 0: Pre-Conference Warm-up
-Registration Day and Ice Breaking Party
Stream 5: Industrial Art Gallery
-From From Drug Approval to International Cooperation
Stream 1: Masters' Mind Honor Hall
-Vision from the World Leaders in Drug Discovery
Stream 6: Young Pharmacists’ Nexus
-New Champions in Drug Discovery
Stream 2: High-end Dialogue
 -How B & R Can Accelerate Drug Discovery
Stream 7: Projects Matchmaking
-Building an Efficient Achievements Transformation Platform
Stream 3: Breaking Research of Drug Discovery
-Frontier Science & Technology Researchof the Future Drug Discovery
Stream 8: Drug Discovery Bazaar
-Posters and Exhibits
Stream 4: Best Practice in Drug Discovery against Unmet Diseases
-From Drug R & D Pipelines to Market Development
Stream 9: Joyful Commune
-Sharing the Diversities for Common Interests
Renowned Speakers

说明: scientificprogram3_clip_image006.jpg Dr. Reuben Matalon, Professor, University of Texas Medical Branch, USA 说明: scientificprogram3_clip_image008.jpg Dr. Marc Cantillon, Chief Medical Officer, Reviva Pharmaceuticals Inc., USA 说明: scientificprogram3_clip_image014.jpg Dr. Raphael Nudelman, Director,  Teva Pharmaceutical Industries Ltd. Israel
说明: scientificprogram3_clip_image016.jpg Dr. Hong Wan, Executive Director and Head, DMPK, China  说明: scientificprogram3_clip_image020.jpg Dr. Thomas Karami, Associate Director, Early Development, Allergan Biologics Ltd., USA 说明: scientificprogram3_clip_image022.jpg  Dr. A. Vieira,  Director
Metabolic Research Lab, Simon Fraser University, Canada
说明: scientificprogram3_clip_image024.jpg Dr. Ken Aoshima, Director of Data Science Laboratory, hhc Data Creation Center, Eisai Co., Ltd. Japan 说明: scientificprogram3_clip_image028.jpg  Dr. Hossein Hosseinkhani, Founder & Chief Scientific Officer, Matrix, Inc., USA 说明: scientificprogram3_clip_image030.jpg Dr. Gerald J. Yakatan, Chairman & CEO, IriSys, LLC,.USA
说明: scientificprogram3_clip_image032.jpg Dr. Juergen Lademann, Professor, Charite - Universitaetsmedizin Berlin, Germany 说明: scientificprogram3_clip_image034.jpg Dr. Anthony W. Coleman, Research Director, University of Lyon, France 说明: scientificprogram3_clip_image038.jpg Dr. Liang Xu, Associate Professor, Beijing Institute of Pharmacology and Toxicology, China
说明: scientificprogram3_clip_image040.jpg Dr. Martin K. Ostermaier, CEO, InterAx Biotech AG, Switzerland 说明: scientificprogram3_clip_image046.jpg Dr. Xiangbing Qi, Director of Chemistry Center, National Institute of Biological Sciences, China 说明: scientificprogram3_clip_image048.jpg Dr. Rony Seger, Professor, Weizmann Institute of Science, Israel
说明: scientificprogram3_clip_image050.jpg Dr. David L. Pompliano, Co-Founder and Chief Scientific Officer, Lodo Therapeutics Corporation, USA 说明: scientificprogram3_clip_image054.jpg Dr. William Fenical, Distinguished Professor, University of California, USA 说明: scientificprogram4_clip_image002.jpg Dr. Arturo Loaiza-Bonilla, Director, Cancer Treatment Centers of America, USA
说明: scientificprogram4_clip_image008.jpg Dr. Kathryn Leake, Director, Oncology Solutions, USA 说明: scientificprogram4_clip_image012.jpg Dr. Ming-Hai Wang, Director,  Texas Tech University HSC School of Pharmacy, USA 说明: scientificprogram4_clip_image020.gif Dr. Steven E. Cohen, Executive Director, Daiichi Sankyo, USA
说明: scientificprogram4_clip_image022.jpg Dr. Renata Gomes, Head of Research  Innovation, University of Oxford, UK 说明: scientificprogram4_clip_image032.jpg Dr. Stanley Schwartz, Emeritus Associate Professor CE Of Medicine, University of Pennsylvania, USA 说明: scientificprogram4_clip_image036.jpg Dr. Jean Michel Scherrmann, Professor, Dean of the Faculty of Pharmaceutical and Biological Sciences, University of Paris, France
说明: scientificprogram4_clip_image045.jpg Dr. Ming Guo, Co-Founder & COO, Ascentage Pharma, China 说明: scientificprogram4_clip_image053.jpg Dr. Tom Hodge, Director of Antiviral Research, Tamir Biotechnology, USA 说明: scientificprogram4_clip_image057.jpg Dr. Peter L. Nara, President and CEO, Biological Mimetics, Inc., USA
说明: scientificprogram4_clip_image063.jpg Dr. Jeffrey Hung, Chief Commercial Officer, GM of cGMP Business, Vigene Biosciences, Inc., USA 说明: scientificprogram4_clip_image080.jpg Dr. Janna Hutz, Senior Director,  Eisai AiM Institute, Eisai Inc. USA 说明: scientificprogram4_clip_image065.jpg Dr. Dave Moskowitz, CEO and Chief Medical Officer, GenoMed, Inc., USA
说明: scientificprogram3_clip_image006.jpg Dr. Stefan Scherer, Vice President, Head Early Development, Strategy and Innovation at Novartis, USA 说明: scientificprogram3_clip_image008.jpg Dr. Zhen Li, Senior Vice President, Discovery Chemistry and Manufacturing, Arrowhead Pharmaceuticals, Inc., USA 说明: scientificprogram3_clip_image014.jpg Dr. Kazuhide Inoue 
Executive Vice President
Kyushu University

Past Conference Report

BIT's 15th Annual Congress of International Drug Discovery Science and Technology-Japan 2017 (IDDST-Japan 2017) which was held in Hyatt Regency Osaka, Osaka, Japan on July 25-27, achieved a consummation. The theme of this conference is "Dedicated to Accelerating Drug Innovation". Over 400 honored guests presented at the ceremony and gave brilliant speeches on invitation, among them are 2010 Nobel Prize Laureate in Chemistry Dr. Ei-ichi Negishi, H. C. Brown Distinguished Professor of Chemistry in Purdue University; Dr. Howard J. Federoff, Vice Chancellor of Health Affairs and Chief Executive Officer of Health System in University of California, Irvine; Dr. Litao Zhang, Vice President of Bristol-Myers Squibb; Dr. Jan Hoflack, Chief Scientific and Operational Officer of Oncodesign SA; Dr. Akiyoshi Suganuma, Group Officer and President of BA-CFU in Medicine Development Center, Eisai Co., Ltd., Dr. David C. Bunton, CEO of REPROCELL Europe Ltd. …etc.

 View More...
Scenery of Jinan

Jinan, capital of Shandong Province, is located on a plain bordering on hilly country at the lower reaches of the Yellow River (Huanghe). Apart from it s beautiful scenery and mild climate, Jinan is known as the "City of Springs." The most scenic spots in Jinan are Daming Lake, Tai San Mountain, Five Dragon Pool and Thousand Buddha Hill.
News Release
Full Program Released 说明:
● Call for Supporting Organizations and Media Partners
● Call for Session Chairs and Speakers 
● Call for Exhibitors and Sponsors
Hosting Organizations

Information Research Center of International Talent, SAFEA

Ji'nan Branch of China Council for The Promotion of International Trade

Jinan Innovation Zone

Operating Organization
BIT Group Global Ltd.
Official Travel Agency
Media Partners

BIT's Upcoming Events
Contact Us

Add: East Area, F11, Building 1, Dalian Ascendas IT Park, 1 Hui Xian Yuan, Dalian Hi-tech Industrial Zone, LN 116025, China]
Tel: 0086-411-84799609, Fax: 0086-411-84796897
Copyright © 2003-2018 BIT Congress Inc.